Cristina Ballart1,2, Mary Cruz Torrico3,4, Gisela Vidal3, Faustino Torrico3,4, Daniel Lozano3,4, Montserrat Gállego1,2, Lilian Pinto3, Ernesto Rojas4, Ruth Aguilar1, Carlota Dobaño1, Sonia Ares-Gomez1, Albert Picado1,5. 1. ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain. 2. Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain. 3. Fundación CEADES Salud y Medio Ambiente, Cochabamba, Bolivia. 4. Facultad de Medicina, Universidad Mayor de San Simón (U.M.S.S.), Cochabamba, Bolivia. 5. Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.
Abstract
BACKGROUND: Tegumentary leishmaniasis (TL) is a parasitic disease that can present a cutaneous or mucocutaneous clinical form (CL and MCL, respectively). The disease is caused by different Leishmania species and transmitted by phlebotomine sand flies. Bolivia has one of the highest incidences of the disease in South America and the diagnosis is done by parasitological techniques. Our aim was to describe the clinical and immunological characteristics of CL and MCL patients attending the leishmaniasis reference center in Cochabamba, Bolivia, in order to gain updated clinical and epidemiological information, to evaluate the diagnostic methods used and to identify biomarkers related to clinical disease and its evolution. METHODOLOGY/PRINCIPAL FINDINGS: The study was conducted from September 2014 to November 2015 and 135 patients with lesions compatible with CL or MCL were included. Epidemiological and clinical data were collected using a semi-structured questionnaire. Two parasitological diagnostic methods were used: Giemsa-stained smears and culture of lesion aspirates. Blood samples obtained from participants were used to measure the concentrations of different cytokines. 59.2% (80/135) were leishmaniasis confirmed cases (CL: 71.3%; MCL: 28.7%). Sixty percent of the confirmed cases were positive by smears and 90.6% were positive by culture. 53.8% were primo-infections. Eotaxin and monokine induced by IFN-γ presented higher serum concentrations in the MCL clinical presentation compared to CL cases and no-cases. None of the cytokines presented different concentrations between primo-infections and secondary infections due to treatment failure. CONCLUSIONS/SIGNIFICANCE: In Bolivia, parasitological diagnosis remains the reference standard in diagnosis of leishmaniasis because of its high specificity, whereas the sensitivity varies over a wide range leading to loss of cases. Until more accurate tools are implemented, all patients should be tested by both smears and culture of lesion aspirates to minimize the risk of false negatives. Our results showed higher concentrations of several cytokines in MCL compared to CL, but no differences were observed between CL and no-cases. In addition, none of the cytokines differed between primary and secondary infections. These results highlight the need of further research to identify biomarkers of susceptibility and disease progression, in addition to looking at the local cellular immune responses in the lesions.
BACKGROUND:Tegumentary leishmaniasis (TL) is a parasitic disease that can present a cutaneous or mucocutaneous clinical form (CL and MCL, respectively). The disease is caused by different Leishmania species and transmitted by phlebotomine sand flies. Bolivia has one of the highest incidences of the disease in South America and the diagnosis is done by parasitological techniques. Our aim was to describe the clinical and immunological characteristics of CL and MCLpatients attending the leishmaniasis reference center in Cochabamba, Bolivia, in order to gain updated clinical and epidemiological information, to evaluate the diagnostic methods used and to identify biomarkers related to clinical disease and its evolution. METHODOLOGY/PRINCIPAL FINDINGS: The study was conducted from September 2014 to November 2015 and 135 patients with lesions compatible with CL or MCL were included. Epidemiological and clinical data were collected using a semi-structured questionnaire. Two parasitological diagnostic methods were used: Giemsa-stained smears and culture of lesion aspirates. Blood samples obtained from participants were used to measure the concentrations of different cytokines. 59.2% (80/135) were leishmaniasis confirmed cases (CL: 71.3%; MCL: 28.7%). Sixty percent of the confirmed cases were positive by smears and 90.6% were positive by culture. 53.8% were primo-infections. Eotaxin and monokine induced by IFN-γ presented higher serum concentrations in the MCL clinical presentation compared to CL cases and no-cases. None of the cytokines presented different concentrations between primo-infections and secondary infections due to treatment failure. CONCLUSIONS/SIGNIFICANCE: In Bolivia, parasitological diagnosis remains the reference standard in diagnosis of leishmaniasis because of its high specificity, whereas the sensitivity varies over a wide range leading to loss of cases. Until more accurate tools are implemented, all patients should be tested by both smears and culture of lesion aspirates to minimize the risk of false negatives. Our results showed higher concentrations of several cytokines in MCL compared to CL, but no differences were observed between CL and no-cases. In addition, none of the cytokines differed between primary and secondary infections. These results highlight the need of further research to identify biomarkers of susceptibility and disease progression, in addition to looking at the local cellular immune responses in the lesions.
Authors: Pablo Bilbao-Ramos; M Auxiliadora Dea-Ayuela; Oscar Cardenas-Alegría; Efraín Salamanca; José Antonio Santalla-Vargas; Cesar Benito; Ninoska Flores; Francisco Bolás-Fernández Journal: Acta Trop Date: 2017-07-24 Impact factor: 3.112
Authors: Tiffany Weinkopff; Christoph Konradt; David A Christian; Dennis E Discher; Christopher A Hunter; Phillip Scott Journal: J Immunol Date: 2016-07-29 Impact factor: 5.422
Authors: Ana L García; Rudy Parrado; Ernesto Rojas; Raúl Delgado; Jean-Claude Dujardin; Richard Reithinger Journal: Am J Trop Med Hyg Date: 2009-05 Impact factor: 2.345
Authors: F Bussolino; M F Di Renzo; M Ziche; E Bocchietto; M Olivero; L Naldini; G Gaudino; L Tamagnone; A Coffer; P M Comoglio Journal: J Cell Biol Date: 1992-11 Impact factor: 10.539
Authors: Daniel Eid; Miguel Guzman-Rivero; Ernesto Rojas; Isabel Goicolea; Anna-Karin Hurtig; Daniel Illanes; Miguel San Sebastian Journal: Trop Med Health Date: 2018-04-17
Authors: Barbara N Harding; Ruth Aguilar; Ana Espinosa; Gemma Castaño-Vinyals; Kyriaki Papantoniou; José Maria Navarrete; Patricia Such Faro; Antonio Torrejón; Carlota Dobaño; Gemma Moncunill; Manolis Kogevinas Journal: Front Immunol Date: 2022-09-02 Impact factor: 8.786